Meeting
2024 ASCO Annual Meeting
Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan.
Authors
Nicholas Mai
Memorial Sloan Kettering Cancer Center, New York, NY
Nicholas Mai , Miriam Klar , Emanuela Ferraro , Maria Bromberg , Yuan Chen , Pedram Razavi , Shanu Modi , Sarat Chandarlapaty , Elaine M. Walsh , Joshua Z. Drago
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Non–Subtype-Specific Breast Cancer Therapies
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1085)
DOI
10.1200/JCO.2024.42.16_suppl.1085
Abstract #
1085
Poster Bd #
63
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.
First Author: Nicholas Mai
Poster
2023 ASCO Annual Meeting
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
First Author: Rachel Occhiogrosso Abelman
Poster
2024 ASCO Breakthrough
Characterization of estrogen receptor mutant breast cancer in 3D cell culture.
First Author: Olivia Mayer
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Unveiling proteomic diversity: A quantitative study of antibody drug conjugate and chemotherapy targets in gastroesophageal cancer.
First Author: Sheeno P. Thyparambil